Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KINE-101 in healthy adult volunteers
NCT07324642Phase 1Completed
- Sponsor
- KINE SCIENCES
- Start
- May 2025
- Primary completion
- Aug 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in acute respiratory distress syndrome (ARDS) comparing KINE-101 with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events at 35 days. Started May 2025; status: completed.
02
Drugs
KINE-101
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT07324642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07324642.